title: Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector.
abstract: In vivo cancer gene therapy approaches for squamous cell carcinoma of the head and neck (SCCHN) based on adenoviral vector-mediated gene delivery have been limited by the suboptimal efficacy of gene transfer to tumor cells. We hypothesized that this issue was due to deficiency of the primary adenoviral receptor, the coxsackie-adenovirus receptor (CAR), on the tumor targets. Studies of CAR levels on SCCHN cell lines confirmed that their relative refractoriness to the adenoviral vector was based on this deficiency. To circumvent this deficiency, we applied an adenoviral vector targeted to a tumor cell marker characteristic of SCCHN. In this regard, integrins of the alpha2beta1 and alpha3beta1 class are frequently overexpressed in SCCHN. Furthermore, these integrins recognize the RGD peptide motif. On this basis, we applied an adenoviral vector genetically modified to contain such a peptide within the HI loop of the fiber protein as a means to alter viral tropism. Studies confirmed that the CAR-independent gene delivery achieved via this strategy allowed enhanced gene transfer efficiencies to SCCHN tumor cells. Importantly, this strategy could achieve preferential augmentation of gene transfer in tumor cells compared with normal cells. The ability to achieve enhanced and specific gene transfer to tumor cells via adenoviral vectors has important implications for gene therapy strategies for SCCHN and for other neoplasms in general.
authors.affiliation: Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.
authors.forename: K
authors.initials: K
authors.lastname: Kasono
authors.forename: J L
authors.initials: JL
authors.lastname: Blackwell
authors.forename: J T
authors.initials: JT
authors.lastname: Douglas
authors.forename: I
authors.initials: I
authors.lastname: Dmitriev
authors.forename: T V
authors.initials: TV
authors.lastname: Strong
authors.forename: P
authors.initials: P
authors.lastname: Reynolds
authors.forename: D A
authors.initials: DA
authors.lastname: Kropf
authors.forename: W R
authors.initials: WR
authors.lastname: Carroll
authors.forename: G E
authors.initials: GE
authors.lastname: Peters
authors.forename: R P
authors.initials: RP
authors.lastname: Bucy
authors.forename: D T
authors.initials: DT
authors.lastname: Curiel
authors.forename: V
authors.initials: V
authors.lastname: Krasnykh
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D014408:Biomarkers, Tumor; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000628:therapy*; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006367:HeLa Cells; D006258:Head and Neck Neoplasms / Q000378:metabolism* / Q000628:therapy*; D006801:Humans; D039201:Integrin alpha3beta1; D016023:Integrins / Q000096:biosynthesis / Q000378:metabolism*; D009842:Oligopeptides / Q000235:genetics / Q000378:metabolism; D038981:Receptors, Collagen; D011991:Receptors, Virus / Q000096:biosynthesis; D014407:Tumor Cells, Cultured
chemical_list: D014408:Biomarkers, Tumor; C568771:CLMP protein, human; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D039201:Integrin alpha3beta1; D016023:Integrins; D009842:Oligopeptides; D038981:Receptors, Collagen; D011991:Receptors, Virus; C047981:arginyl-glycyl-aspartic acid